CSBio CSBio

X
[{"orgOrder":0,"company":"Nanobiotix","sponsor":"HSBC","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Nanobiotix Secures \u20ac10M in Non-Dilutive Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nanobiotix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.

            Lead Product(s): Hafnium Oxide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: HSBC

            Deal Size: $11.1 million Upfront Cash: Undisclosed

            Deal Type: Financing June 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY